Leavell Investment Management Inc. boosted its holdings in shares of Laboratory Corp. of America Holdings (NYSE:LH) by 1.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,533 shares of the medical research company’s stock after buying an additional 100 shares during the period. Leavell Investment Management Inc.’s holdings in Laboratory Corp. of America were worth $846,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also made changes to their positions in the company. JFS Wealth Advisors LLC acquired a new position in shares of Laboratory Corp. of America in the fourth quarter valued at about $26,000. Evolution Wealth Advisors LLC purchased a new position in Laboratory Corp. of America during the fourth quarter worth approximately $29,000. Bremer Trust National Association purchased a new position in Laboratory Corp. of America during the fourth quarter worth approximately $31,000. Quantamental Technologies LLC purchased a new position in Laboratory Corp. of America during the fourth quarter worth approximately $39,000. Finally, Shine Investment Advisory Services Inc. boosted its position in Laboratory Corp. of America by 30.7% during the first quarter. Shine Investment Advisory Services Inc. now owns 277 shares of the medical research company’s stock worth $42,000 after purchasing an additional 65 shares in the last quarter. 91.51% of the stock is currently owned by institutional investors.
Shares of NYSE LH opened at $152.61 on Wednesday. The stock has a market cap of $15.70 billion, a price-to-earnings ratio of 13.85, a price-to-earnings-growth ratio of 1.80 and a beta of 1.15. The company has a quick ratio of 1.38, a current ratio of 1.51 and a debt-to-equity ratio of 0.87. Laboratory Corp. of America Holdings has a 1 year low of $119.38 and a 1 year high of $190.35.
Laboratory Corp. of America (NYSE:LH) last announced its quarterly earnings results on Thursday, February 7th. The medical research company reported $2.52 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.48 by $0.04. The business had revenue of $2.79 billion for the quarter, compared to analyst estimates of $2.78 billion. Laboratory Corp. of America had a return on equity of 17.05% and a net margin of 8.43%. The company’s quarterly revenue was up 1.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.45 EPS. On average, equities research analysts expect that Laboratory Corp. of America Holdings will post 11.22 EPS for the current fiscal year.
Several equities analysts have recently weighed in on LH shares. Morgan Stanley set a $177.00 target price on Laboratory Corp. of America and gave the company a “buy” rating in a research report on Thursday, December 20th. Zacks Investment Research upgraded Laboratory Corp. of America from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd. Bank of America downgraded Laboratory Corp. of America from a “neutral” rating to an “underperform” rating in a research report on Thursday, January 3rd. ValuEngine cut Laboratory Corp. of America from a “hold” rating to a “sell” rating in a report on Monday, January 7th. Finally, TheStreet cut Laboratory Corp. of America from a “b-” rating to a “c+” rating in a report on Friday, January 11th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and ten have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $175.50.
In related news, Director R Sanders Williams sold 1,038 shares of the company’s stock in a transaction that occurred on Wednesday, February 13th. The stock was sold at an average price of $147.00, for a total value of $152,586.00. Following the sale, the director now owns 8,924 shares of the company’s stock, valued at approximately $1,311,828. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.74% of the stock is owned by insiders.
ILLEGAL ACTIVITY NOTICE: “Laboratory Corp. of America Holdings (LH) Position Lifted by Leavell Investment Management Inc.” was reported by Macon Daily and is the sole property of of Macon Daily. If you are accessing this story on another website, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this story can be viewed at https://macondaily.com/2019/04/17/laboratory-corp-of-america-holdings-lh-position-lifted-by-leavell-investment-management-inc.html.
Laboratory Corp. of America Profile
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, LabCorp Diagnostics (LCD) and Covance Drug Development. It offers various clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually-transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests.
Recommended Story: How can you know how many shares are floating?
Receive News & Ratings for Laboratory Corp. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corp. of America and related companies with MarketBeat.com's FREE daily email newsletter.